Jim Cramer says one stock hitting new highs is still a screaming buy

On August 11, Jim Cramer made an enthusiastic triple buy recommendation on Hinge Health (HNGE) during his Mad Money Lightning Round. This particular stock had yet to gain widespread recognition among the investing community. Cramer's conviction in Hinge Health was backed by its impressive performance metrics. As of August 10, the stock had surged by 85.83% year to date, reaching a record high of $93.13.

Furthermore, Hinge Health reported record second-quarter 2026 results on August 4, demonstrating remarkable growth and financial resilience. The company's revenue increased by 53% year over year, reaching $213 million. Additionally, Hinge Health tripled its free cash flow to nearly $100 million and raised its full-year guidance.

The company's innovative AI-powered platform, designed to provide automated, personalized musculoskeletal (MSK) care at scale to employers and health plans, was the driving force behind its success. Hinge Health was founded in 2014 by Daniel Perez and Gabriel Mecklenburg, both of whom had firsthand experience with musculoskeletal injuries and the challenging recovery process.

Their expertise led to the creation of an effective solution for chronic pain, acute injury, and post-surgical rehabilitation. Hinge Health's business model targets the MSK market, partnering with corporations and health plans to deliver digital physical therapy and care management, ultimately reducing downstream medical costs associated with costly health conditions.

Hinge Health's client base has grown significantly, serving 2,929 clients as of June 30, 2026, marking a 24% increase year over year. More than half of the Fortune 100 companies are now part of Hinge Health's client portfolio. The company's LTM billings reached $861.8 million, a 52% increase year over year. The second-quarter financial performance was strong across all key metrics, with revenue growing 53% year over year, non-GAAP operating income more than doubling YoY, and free cash flow growing by three times, with a free cash flow margin of 47%.

These impressive financial results led Jim Cramer to make a strong buy recommendation on Hinge Health, emphasizing the company's impressive growth and sustainable business model.